<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04537910</url>
  </required_header>
  <id_info>
    <org_study_id>18124</org_study_id>
    <secondary_id>J2X-MC-PYAG</secondary_id>
    <nct_id>NCT04537910</nct_id>
  </id_info>
  <brief_title>A Study of LY3819253 (LY-CoV555) in Healthy Participants</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Participant- and Investigator-Blind, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of LY3819253 Administered Subcutaneously to Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety and tolerability of LY3819253 when it is&#xD;
      given by injection just under the skin to healthy participants. Blood tests will be done to&#xD;
      check how much LY3819253 is in the bloodstream and how long the body takes to eliminate it.&#xD;
      Participation could last up to 16 weeks and may include up to six visits to the study center,&#xD;
      with a one-week overnight stay.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2, 2020</start_date>
  <completion_date type="Actual">December 28, 2020</completion_date>
  <primary_completion_date type="Actual">December 28, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time 0 to Infinity (AUC[0-inf])</measure>
    <time_frame>Day 1 through Day 85</time_frame>
    <description>PK: AUC(0-inf)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3819253</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3819253 administered subcutaneously (SC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3819253</intervention_name>
    <description>Administered SC.</description>
    <arm_group_label>LY3819253</arm_group_label>
    <other_name>LY-CoV555</other_name>
    <other_name>Bamlanivimab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are overtly healthy as determined by medical evaluation including medical history and&#xD;
             physical examination&#xD;
&#xD;
          -  Are willing to follow study procedures, including having nasal or nasopharyngeal swabs&#xD;
             collected&#xD;
&#xD;
          -  Have a body mass index (BMI) within the range of greater than or equal to (≥)18.5 to&#xD;
             less than (&lt;)35 kilograms per square meter (kg/m²)&#xD;
&#xD;
          -  Male participants must agree to adhere to contraception restrictions&#xD;
&#xD;
          -  Female participants must be of non-childbearing potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have or have had known or suspected severe acute respiratory syndrome coronavirus 2&#xD;
             (SARS-CoV-2) infection&#xD;
&#xD;
          -  Have a history or presence of cardiovascular (including hypertension), respiratory,&#xD;
             hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, or&#xD;
             neurological disorders that, in the opinion of the investigator, are capable of&#xD;
&#xD;
               -  Significantly altering the absorption, metabolism, or elimination of drugs&#xD;
&#xD;
               -  Constituting a risk while taking the investigational product, or&#xD;
&#xD;
               -  Interfering with the interpretation of data&#xD;
&#xD;
          -  Have significant allergies to humanized monoclonal antibodies (mAbs)&#xD;
&#xD;
          -  Have any of the following that are clinically significant:&#xD;
&#xD;
               -  Multiple or severe drug allergies, or&#xD;
&#xD;
               -  Intolerance to topical corticosteroids, or&#xD;
&#xD;
               -  Severe posttreatment hypersensitivity reactions (including, but not limited to,&#xD;
                  erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal&#xD;
                  necrolysis, or exfoliative dermatitis)&#xD;
&#xD;
          -  Have had lymphoma, leukemia, or any malignancy within the past 5 years, except for&#xD;
             basal cell or squamous epithelial carcinomas of the skin that have been resected with&#xD;
             no evidence of metastatic disease for 3 years&#xD;
&#xD;
          -  Have had breast cancer within the past 10 years&#xD;
&#xD;
          -  Show evidence of human immunodeficiency virus (HIV) infection and/or positive human&#xD;
             HIV antibodies&#xD;
&#xD;
          -  Show evidence of current hepatitis C (that is, test positive for anti-hepatitis C&#xD;
             antibody with confirmed presence of hepatitis C virus [HCV] ribonucleic acid [RNA])&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Inc</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 1, 2020</study_first_submitted>
  <study_first_submitted_qc>September 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2020</study_first_posted>
  <last_update_submitted>January 20, 2021</last_update_submitted>
  <last_update_submitted_qc>January 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>November 1, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

